Exelixis
EXEL
#1702
Rank
NZ$17.27 B
Marketcap
$60.50
Share price
0.09%
Change (1 day)
59.67%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): NZ$0.96 Billion

According to Exelixis's latest financial reports the company's current earnings are NZ$2.08 Billion. In 2023 the company made an earning of NZ$0.45 Billion, an increase over its 2022 earnings that were of NZ$0.41 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) NZ$0.96 B111.5%
2023 NZ$0.45 B9.89%
2022 NZ$0.41 B-20.33%
2021 NZ$0.52 B124.82%
2020 NZ$0.23 B-67.14%
2019 NZ$0.70 B-11.94%
2018 NZ$0.80 B185.09%
2017 NZ$0.28 B-325.82%
2016 -NZ$0.13 Billion-58.12%
2015 -NZ$0.3 Billion-37.61%
2014 -NZ$0.48 Billion9.75%
2013 -NZ$0.44 Billion65.96%
2012 -NZ$0.27 Billion-291.63%
2011 NZ$0.13 B-195.59%
2010 -NZ$0.15 Billion-42.17%
2009 -NZ$0.25 Billion-18.98%
2008 -NZ$0.31 Billion-6.99%
2007 -NZ$0.33 Billion46.3%
2006 -NZ$0.23 Billion33.25%
2005 -NZ$0.17 Billion-30.92%
2004 -NZ$0.25 Billion44.29%
2003 -NZ$0.17 Billion12.86%
2002 -NZ$0.16 Billion22.79%
2001 -NZ$0.13 Billion60.14%
2000 -NZ$76.34 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
NZ$7.42 B 595.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$13.19 B 1,134.83%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$26.66 B 2,395.89%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$12.26 Billion-1,246.85%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$8.33 B 679.96%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$32.75 B 2,966.31%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$12.36 B 1,057.35%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$79.81 Million-107.47%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$51.72 Million-104.84%๐Ÿ‡บ๐Ÿ‡ธ USA